AML ALL Clinical As described previously features 量后 immunoph CDI3 CD14 TdT(95%+) genotyping CD15 CD64 B: CD19 T: CD2 Karyotypic M2: t(8: 21) changes M31517)维甲酸治疗Pre-B: Hyperdiploidy M4:inv(16)/del(16) t(12;21);Ph prognosis Devastating disease Good: 2-10 yrs, pre-BClinical features As described previously immunoph enotyping CD13,CD14, CD15, CD64 TdT (95% +) B: CD19 T: CD2 AML ALL Karyotypic changes Pre-B: Hyperdiploidy t (12;21) ; Ph prognosis Good:2-10 yrs, pre-B Devastating disease M2: t(8;21) M3:t(15;17) 维甲酸治疗 M4: inv(16) /del(16)